会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 54. 发明授权
    • Methods of making fused ring compounds
    • 稠环化合物的制备方法
    • US09139571B2
    • 2015-09-22
    • US13314735
    • 2011-12-08
    • Meng HeAnil Kumar
    • Meng HeAnil Kumar
    • C07D413/00C07C41/00C07C39/12C07D405/04C07D407/04
    • C07C39/17C07C37/11C07C41/01C07C51/353C07C2602/08C07C2603/40C07D307/33C07D311/94C07D405/04C07D407/04
    • The present invention relates to methods of making fused ring compounds, such as indeno-fused naphthols, and fused ring indenopyran compounds, such as indeno-fused naphthopyrans, that each employ an unsaturated compound represented by the following Formula II. Referring to the unsaturated compound of Formula II: Ring-A can be selected from optionally substituted aryl (e.g., phenyl); m can be, for example, from 0 to 4; R1 for each m can be selected from optionally substituted hydrocarbyl (e.g., C1-C6 alkyl) optionally interrupted with at least one linking group (e.g., —O—); and R3 and R16 can each be independently selected from, for example, hydrogen or optionally substituted hydrocarbyl, such as C1-C8 alkyl. When Ring-A is a phenyl group, the unsaturated compound represented by Formula II can be referred to as an unsaturated indanone acid/ester compound, or an indenone acid/ester compound (depending on whether R16 is hydrogen, or an optionally substituted hydrocarbyl group).
    • 本发明涉及使稠合环化合物如茚并稠合的萘酚和茚并稠合的萘并吡喃化合物,如茚并稠合的萘并吡喃,各自使用由下式II表示的不饱和化合物的方法。 关于式II的不饱和化合物:环-A可以选自任选取代的芳基(例如苯基); m可以是例如0至4; 每个m的R 1可以选自任选被至少一个连接基团(例如-O-)中断的任选取代的烃基(例如C 1 -C 6烷基); 并且R 3和R 16各自独立地选自例如氢或任选取代的烃基,例如C 1 -C 8烷基。 当环A是苯基时,由式II表示的不饱和化合物可以称为不饱和茚酮酸/酯化合物或茚酮酸/酯化合物(取决于R 16是氢还是任选取代的烃基 )。
    • 58. 发明申请
    • PHOTOCHROMIC COMPOUNDS
    • 光敏化合物
    • US20080051575A1
    • 2008-02-28
    • US11925044
    • 2007-10-26
    • Anil KumarMeng HeTerry KellarForrest Blackburn
    • Anil KumarMeng HeTerry KellarForrest Blackburn
    • C07D405/14C07D315/00C07J17/00C07D405/02
    • C07D405/14C07D311/94C07D405/10C07D498/10C09B57/00C09K19/60G02B5/23G02B5/3016G02B5/3025G02F1/1335G03C1/73
    • Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other non-limiting embodiments relate to photochromic-dichroic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. For example, one non-limiting embodiment provides a thermally reversible, photochromic compound adapted to have at least a first state and a second state, wherein the thermally reversible, photochromic compound has an average absorption ratio greater than 2.3 in at least one state as determined according to CELL METHOD. Another non-limiting embodiment provides a photochromic compound comprising: (a) at least one photochromic group chosen from a pyran, an oxazine, and a fulgide; and (b) at least one lengthening agent L attached to the at least one photochromic group and represented by the formula —[S1]c-[Q1-[S2]d]d′-[Q2-[S3]e]e′-[Q3-[S4]f]f′—S5—P, which is described herein.
    • 本文公开的各种非限制性实施方案通常涉及光致变色化合物,其可以是热可逆的或不可逆的,以及由其制成的制品。 其它非限制性实施方案涉及光致变色二色性化合物,其可以是热可逆的或不可逆的,以及由其制备的制品。 例如,一个非限制性实施方案提供了适于具有至少第一状态和第二状态的热可逆的光致变色化合物,其中所述热可逆的光致变色化合物在至少一种状态中的平均吸收比大于2.3,如所确定的 根据细胞方法 另一个非限制性实施方案提供了一种光致变色化合物,其包含:(a)至少一种选自吡喃,恶嗪和吡啶的光致变色基团; 和(b)至少一个延长剂L,其连接到所述至少一个光致变色基团并由式 - [S 1 -C 3 - d - [Q 2 - ] - [S 2 > 3 > - >这里描述的F-5 S-5。